40 results about "Human intestine" patented technology

The invention belongs to the technical field of plant active peptides, and particularly relates to a red kidney bean hypoglycemic active peptide and application thereof. The amino acid sequences of the hypoglycemic active peptide are FFGGPAF, SAKPFFSGL and PPGHPFVTF. The invention further discloses a preparation method of the hypoglycemic active peptide. FF, SL and PF for short. The polypeptide is prepared through enzymolysis of red kidney bean protein, and the polypeptide is identified by utilizing ultrafiltration separation and LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry); the hypoglycemic active peptides which are high in hypoglycemic effect, free of toxicity, carcinogenicity and sensitization and capable of being absorbed by human intestinal tracts are screened out through a bioinformatics method and molecular docking, then the screened hypoglycemic active peptides and alpha-glucosidase are subjected to molecular docking, and finally three hypoglycemic active peptides FF, SL and PF are screened out. The invention finds that the hypoglycemic active peptides FF, SL and PF have high inhibitory activity on alpha-glucosidase, can obviously promote glucose consumption of insulin resistance model cells, and can be used for preparing hypoglycemic drugs, food and health care products.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus mucus BU360 with the function of improving uric acid, blood fat and blood glucose metabolism and application of the lactobacillus mucus BU360. The preservation number of the lactobacillus fermentum BU360 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.33032. The lactobacillus fermentum BU360 provided by the invention has the advantages that the preservation number is CGMCC No.33032; the lactobacillus mucus BU360 can efficiently degrade guanosine and inosine which are precursor substances for synthesizing uric acid and directly degrade the uric acid, thalli, cell contents and metabolites of the lactobacillus mucus BU360 can inhibit the activity of xanthine oxidase and relieve HUA, and the lactobacillus mucus BU360 can directly degrade cholesterol and inhibit the activity of alpha-glucosidase and alpha-amylase, so that the lactobacillus mucus BU360 can be used for preparing the uric acid. The polypeptide has potential capability of improving blood fat and blood glucose metabolism abnormality, and assists in treatment of HUA; besides, the strain has relatively strong acid-resistant and cholate-resistant characteristics, can smoothly reach the intestinal tract of a human body, has relatively good safety on sensitivity of various antibiotics, and lays a foundation for development of related probiotic products. The lactobacillus mucus BU360 has a wide application prospect in the aspect of preparing products for relieving HUA, improving blood fat and blood glucose metabolism and the like.

This invention belongs to the field of microbial technology, specifically relating to a strain of *Pediococcus pentosaceus* SUN02 with acetylcholinesterase inhibitory activity and its applications. This *Pediococcus pentosaceus* SUN02 is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 29705. The *Pediococcus pentosaceus* SUN02 provided by this invention exhibits strong acid and bile salt resistance, good tolerance in simulated gastric and intestinal fluids, and can successfully reach the human intestine. *Pediococcus pentosaceus* SUN02, in its bacterial suspension and inactivated cells, possesses strong acetylcholinesterase inhibitory activity, produces γ-aminobutyric acid (GABA), and has antioxidant and other probiotic functions. Its application in probiotic products may help improve Alzheimer's disease, enhance learning and memory abilities, regulate mood, and improve sleep.

The invention discloses an easily absorbable organic calcium powder containing mineral elements and a preparation process thereof, and the raw materials comprise, by weight, 50-70 parts of an organic calcium source, 20-30 parts of a plant protein source, 5-10 parts of a polybasic amino acid chelate, 0.01-0.03 part of vitamin D3, 1-3 parts of trace mineral elements, 0.5-1.5 parts of compound protease, 0.1-0.3 part of a food-grade surfactant, and 100-150 parts of deionized water. The invention relates to the technical field of nutritional supplements. According to the mineral element-containing easy-to-absorb organic calcium powder and the preparation process, vegetable protein is converted into amino acid through biological enzymolysis, the amino acid and calcium carbonate are subjected to a chelation reaction to generate amino acid chelated calcium, and compared with traditional organic calcium, chelated calcium is more easily absorbed by human intestinal tracts; meanwhile, calcium, magnesium and phosphorus are synergistically matched, magnesium can activate vitamin D3, the vitamin D3 further promotes absorption of calcium, phosphorus and calcium form a reasonable proportion, deposition of calcium in bones is enhanced, and calcium ions can be absorbed in intestinal tracts without depending on gastric acid by adopting a bicyclic stable chelating structure.

The invention belongs to the technical field of bioengineering, and discloses a specific identification primer and method for lactobacillus curvatus in human intestinal tracts and application. The identification primer comprises an upstream primer COG3825F1 and a downstream primer COG3825R1, the nucleotide sequence of the upstream primer COG3825F1 is 5 '-GTCACAACAAGACCGATTT-3', and the nucleotide sequence of the downstream primer COG3825R1 is 5 '-CTGTTTCTACAACTTGTGCT-3', and the nucleotide sequence of the upstream primer COG3825F1 and the nucleotide sequence of the downstream primer COG3825R1 are 5 '-GTCACAACAAGACCGATTT-3'. The specific COG3825 gene of the lactobacillus flexus is screened to serve as a target sequence design primer, and PCR, gel electrophoresis and qPCR verification show that the primer has extremely high specificity and sensitivity and can accurately distinguish the lactobacillus flexus from the related lactobacillus and other common intestinal bacteria under the complex micro-ecological background of the human intestinal tract; the identification method based on the primer is easy and convenient to operate and accurate in result, qualitative and quantitative detection of the lactobacillus brevis in human intestinal samples, food samples and other environment samples can be achieved, and important technical support is provided for related research, application development and micro-ecological monitoring of the lactobacillus brevis.

The present invention discloses an intestinal flow field modeling method and device based on bidirectional fluid-solid coupling. The method comprises: S1, collecting intestinal multimodal data; wherein the multimodal data includes geometric parameters, motion characteristics, content statistics and wall stress and strain data of the intestine; S2, reconstructing a three-dimensional geometric model of the human intestine; S3, preprocessing the established intestinal geometric model by format conversion and simplification and modification; S4, dividing the preprocessed model into a fluid domain and a solid domain, and establishing a bidirectional fluid-solid coupling model architecture; S5, performing fluid domain simulation settings: simulating multiphase flow contents and setting a fluid simulation model; S6, performing solid domain simulation settings: setting intestinal wall material parameters and simulating intestinal movement; S7, achieving bidirectional fluid-solid coupling and simulating the intestinal flow field. The method takes into account the bidirectional interaction between the intestinal wall solid domain and the intestinal content fluid domain, achieving more accurate intestinal flow field simulation.

The invention relates to a preparation method of a low-calorie and low-carbohydrate weight-losing main food, which is characterized in that the low-calorie and low-carbohydrate weight-losing main food with the content of 200-350 kilocalories is produced by utilizing the functional effect that insoluble coarse dietary fibers can be expanded into about 7 times of volume after entering human intestinal tracts and absorbing water; enteral emptying is prolonged, so that hunger sensation can be reduced, and happiness of the human body is increased. Food with low calorie and extremely low carbohydrate content is produced and processed by using a method for removing components except insoluble coarse dietary fibers by using a biological function containing cellulase and a compound enzyme of the cellulase and the like; the invention relates to a preparation method of dietary fiber food such as soybean dreg powder, wheat bran powder and the like, wherein the intake of the soybean dreg powder is reduced by 500-1000 kilocalories per day on the basis of target energy.

The invention develops a method for absolute quantification of fungal population based on a Pacbio three-generation long fragment sequencing platform and application thereof, and belongs to the technical field of microbial amplicon detection. According to the method, the synthesized chimeric DNA is used as an internal standard, and a fungal community in a sample is absolutely quantified on the basis of an amplicon high-throughput sequencing platform. The specific method comprises the following steps: directly adding the synthesized chimeric DNA into an environmental sample; extracting genome DNA of the environment sample; carrying out high-throughput sequencing on the ITS full-length sequence of the fungus through PCR amplification; the high-throughput sequencing results calculate the relative abundance and absolute abundance of the amplicon family (e.g., the copy number of fungal ITS per unit mass sample). A highly complex environmental sample is taken as a research object to prove that the method can sensitively and accurately quantify the absolute abundance of a specific group. The method is widely applicable to microbial community analysis of samples from different sources, including environmental samples from soil, samples from plant tissues, samples from human intestinal tracts, and samples from food samples. The method disclosed by the invention is simple to operate, accurate in detection and wide in application, and has a wide market prospect in identification and analysis of microbial communities.

The invention belongs to the technical field of medicines, and particularly relates to an agaricus blazei murill extract and application thereof in treating intestinal mucositis. The invention provides application of an agaricus blazei murill extract FA-2-b-beta in preparation of a medicine for preventing, treating and / or relieving intestinal mucositis. The FA-2-b-beta can obviously improve 5-FU induced intestinal mucositis, obviously promote human intestinal epithelial cell proliferation, recover intestinal barriers and resist toxic and side effects of chemotherapy.

The invention discloses a specific primer for identifying sake lactobacillus brevis, which comprises an upstream primer COG3681F1: 5 '-SCTGCGATGTCCAACTCT-3', and a downstream primer COG3681F1: 5 '-SCTGCGATGTCCACTCT-3', and the Tm is 55 DEG C; the invention discloses a kit for detecting lactobacillus sake brevibacillus, which comprises a forward primer COG3681F1, a reverse primer COG3681R1: 5 '-CGAATCAGCTGTTCCTCAGT-3', Tm of which is 55 DEG C. A probe matched with the primers COG3681F1 and COG3681R1 is 5 '-CTGCCGCTACGCTGACCG-3', the 5'end is marked with an FAM report fluorophore, and the 3 'end is marked with a BHQ1 quenching fluorophore. According to the kit, the efficient and specific detection of lactobacillus sake brevibacillus is realized, and whether the strain is lactobacillus sake brevibacillus can be judged in a short time.

The invention relates to an establishment method of a high-fat induced intestinal organ injury model and an injury intervention method for the model. The establishment method comprises the following steps: step A, preparation: preparing colon cells, PBMC cells and an organ-like culture chip for later use; step B, colon barrier construction: inoculating colon cells to the surface of a barrier membrane on the lower side of a culture chip by using an organoid culture chip to obtain a colon barrier model; step C, constructing a co-culture model, and inoculating PBMC cells to the basal side of the colon barrier on the basis of the colon barrier to obtain a human colon barrier-PBMC co-culture model; d, constructing a damage model, and performing damage treatment on the co-culture model by using a treating fluid to obtain the damage model; according to the invention, the barrier function organ-like chip is used, a human intestinal cell-PBMC co-culture model is formed by utilizing human intestinal organs and PBMC cells, and OXLDL / palmitic acid can play a role in an injured intestinal organ barrier model and form a high-fat induced intestinal organ injury model through the prepared injury treating fluid.

This invention discloses an intelligent bionic artificial anus system, comprising: a sphincter module, a pressure sensor, and a controller. The pressure sensor and controller are disposed within the sphincter module. The sphincter module is located on the outer side of the human intestine and constricts the intestine. The pressure sensor detects a first pressure emanating from inside the intestine and sends the first pressure value to the controller. The controller issues an opening command when the first pressure value meets a first condition. The sphincter module reduces the external pressure applied to the intestine based on the opening command, causing the intestine to open. The controller issues a closing command when the first pressure value meets a second condition. The sphincter module closes the intestine based on the closing command. This allows patients who have had their anus removed to regain anal function, enabling them to defecate, work, live, and exercise normally without the need for a stoma, thus improving their quality of life.

The invention belongs to the technical field of intestinal microorganisms, and particularly relates to bacteroides polydeformation ZF-8 and application thereof in preparation of drugs and food for treating and / or preventing inflammatory bowel diseases. The invention relates to a bacterial strain, in particular to a bacterial strain ZF-8, and the bacterial strain ZF-8 is a bacterial strain ZF-8. The strain is separated from the intestinal tract of a healthy human body and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M 2025618. The bacterial strain can protect colorectal mucosa from being damaged and repair the damaged intestinal mucosa, so that symptoms such as loose stool, hematochezia and colorectal shortening are improved, weight loss caused by intestinal injury and inflammation is relieved, and finally, the inflammatory bowel disease is treated.

Cineole for use in reducing pathogenic germs in the human intestine and in reducing the colonization of the human intestine with pathogenic germs and equally for use in increasing the colonization of the human intestine with health-promoting or non-pathogenic germs.

The present invention discloses a sustained-release suspension of trimebutine maleate resin complex, and its raw materials by weight include: 190-210 parts of trimebutine maleate resin complex, 18-22 parts of xanthan gum, 0-20 parts of tragacanth gum, 15-17 parts of citric acid, 4-6 parts of propylene glycol, and 240-260 parts of water. The present invention also discloses a preparation method of the above-mentioned sustained-release suspension of trimebutine maleate resin complex, which comprises the following steps: dissolving xanthan gum and tragacanth gum in water, then successively adding citric acid and propylene glycol and mixing evenly, and then adding trimebutine maleate resin complex and stirring evenly to obtain the sustained-release suspension of trimebutine maleate resin complex. The sustained-release suspension of trimebutine maleate resin complex of the present invention can achieve site-specific sustained release in the human intestine, continuously exert its drug effect, and the suspension has good stability and no bitter taste, improving the compliance of patients in taking the medicine.

The invention discloses an intestinal microbial marker combination for noninvasive diagnosis of intrahepatic cholestasis and application of the intestinal microbial marker combination, and belongs to the technical field of medical treatment. According to the invention, by integrating metagenome sequencing and a machine learning algorithm, a group of intestinal microbial marker combination composed of 12 bacterial species is screened; the bacillus subtilis specifically comprises atypical virenoccus virens, Wilbionan isonibacterium, Brawtella, mucophilic protein anaerobic corynebacterium, bacteroides simplex, a clostridium AT4 strain, sargassum purpurascens, lawsonia sacchariflora, clostridium enteric, actinomycetes grignard, brassicaceae marsi Q3528 and bile vowenii. The AUC of a diagnosis model constructed based on the marker combination on an independent test set reaches 0.871, and the sensitivity and the specificity reach 86.7% and 81.3% respectively. The invention provides a non-invasive, simple, convenient and accurate auxiliary diagnosis tool for intrahepatic cholestasis, and has excellent clinical transformation prospects.

The invention relates to the technical field of food processing, and discloses a compound beverage based on jerusalem artichoke, synanthrin and fructus momordicae and a preparation method thereof, and the preparation method at least comprises the following steps: S1, preparing raw materials; s2, performing pretreatment; s3, blending; s4, performing homogenizing; and S5, filling and sterilizing. According to the invention, the synanthrin and the fructus momordicae are scientifically matched, so that the beverage is endowed with good taste, the calorie of the beverage is greatly reduced, the beverage is extremely attractive to people who pay attention to healthy lifestyles, and health risks caused by excessive calorie intake can be effectively avoided while the people enjoy the delicious beverage; the fructus momordicae is rich in various beneficial ingredients and has the effects of clearing heat, moistening the lung, relieving sore-throat, opening voice, lubricating the intestines, relaxing the bowels and the like, so that the health value of the beverage is further improved.

The present application discloses a drivable integrated drug-releasing and sampling capsule, which relates to the field of medical device technology. It can achieve targeted release of drugs at precise locations and precise dosages in the human intestine, as well as almost non-invasive tissue sampling. The capsule includes a shell; a first external thread and an internal thread with the same rotation direction are provided on the shell; a first drug outlet is provided at the tail, and a sampling needle is provided at the head; a sleeve and a plunger are provided in the shell; the sleeve is a cylinder with an opening at one end, and the plunger includes a threaded section and an optical axis section; a second external thread that matches the internal thread is provided on the threaded section, the optical axis section extends into the interior of the sleeve and can slide axially in the sleeve, and the bottom surface of the optical axis section, the bottom surface of the sleeve and the inner side wall of the sleeve form a drug storage cavity; a second drug outlet is provided on the side wall of the drug storage cavity; the plunger can push the sleeve to move axially along the shell; when the sleeve runs to the bottom of the shell, the first drug outlet and the second drug outlet are connected; the first external thread and the second external thread are both magnetic.

The invention relates to lactobacillus acidophilus CBBM004 and application thereof in intestinal health care, kidney health care and hypoglycemic products, and belongs to the technical field of microorganism application. The lactobacillus acidophilus CBBM004 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on March 20, 2025, the preservation number is CGMCC No.33903, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the lactobacillus acidophilus is separated from human intestinal tracts. The strain has a remarkable application effect in intestinal health care, kidney health care and hypoglycemic products. The application forms of the strain comprise powder, granules, capsules, tablets, pills, drops or liquid dosage forms, and a new choice is provided for development of related food, health care products or medicine products.

The invention belongs to the field of probiotics and application thereof, and particularly relates to a humanized bifidobacterium animalis probiotic strain and application thereof in preparation of drugs for preventing or treating atopic dermatitis. The preservation number of the humanized bifidobacterium animalis is GDMCC No: 65044, the preservation unit is called GDMCC for short, and active metabolites secreted by the strain comprise acetate. The animal bifidobacterium disclosed by the invention has the advantages that the animal bifidobacterium is derived from the intestinal tract of a healthy individual, can normally survive in the intestinal tract of a human body, has no toxic or side effect and has relatively high safety. Besides, the strain can be used for building a microorganism-immune cell co-culture platform in a body, and the type 2 immune inflammation of an AD patient is effectively improved by regulating and controlling Th1 / Th2 immune balance. By means of targeted supplementation of deficient protective strains of patients, a new prevention and treatment means can be provided for AD patients.

The invention provides a strain level PMAxx-qPCR method and application, and belongs to the technical field of microbiological detection. The invention provides a PMAxx-qPCR method, which can accurately, qualitatively and quantitatively detect live bacteria in an excrement sample and distinguish exogenous strains from natural microbiota, and is high in sensitivity and good in specificity. According to the embodiment of the invention, verification is carried out by taking a bifidobacterium longum subsp. Longum as an example, and by adding live and dead bacterial strains, the method provided by the invention is proved to be capable of accurately identifying and quantifying live bacterial strains in the excrement sample at the bacterial strain level and distinguishing exogenous bacterial strains from local microbiota. By utilizing the scheme of the invention, the feasible dosage form of the probiotics can be evaluated, the effect of the probiotics on intestinal microorganisms can be evaluated, and the survival and colonization effectiveness of the probiotics in human intestinal tracts can be evaluated.

A non-invasive measurement method and device for measuring intestinal core temperature through the navel. The device is located on the navel surface of the human abdomen and is used to detect the intestinal core temperature of the human body. It includes a heat-conducting lower cover and a heat-insulating upper shell. A circuit board is arranged inside the heat-conducting lower cover and the heat-insulating upper shell. The circuit board is provided with an infrared temperature sensor, an ambient temperature sensor, an IC chip, a data transmission chip and a power supply. A measuring hole is arranged on the heat-conducting lower cover at a position corresponding to the infrared temperature sensor. The core temperature value close to the navel intestinal tract is calculated by the value detected by the sensor in the device, and the temperature information is uploaded to the host computer for display and storage through the communication module. The present invention realizes convenient, fast, non-invasive, real-time and accurate measurement of the core temperature closest to the human intestinal tract, and effectively solves the defect that the existing non-invasive temperature measurement technology cannot measure the core temperature of the human intestinal tract quickly, accurately, continuously, in real time and for a long time.

Provided herein are probiotic compositions and methods for treating animals or humans, or human or animal feed, or a surface in contact therewith comprising: feeding or providing a feed, supplement, additive, or food to animals or humans with a composition comprising one or more probiotic bacteria, supernatant, extract, broth, or fermentate thereof, selected from L28, L3AL3 A, L20-B, J7, J14, J27, J43, J16, J34, J25, L5-A and J19 provided in an amount sufficient to be at least one of: bactericidal against bacteria selected from at least one of: spore-forming bacteria, gram positive bacteria, gram negative bacteria, or combinations thereof, in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, reduce carriage, reduce fecal shedding, or reduce gut infection and inflammation.

The invention belongs to the technical field of biological medicine, and particularly relates to an intestinal fungus microorganism model for noninvasive diagnosis of an atrial fibrillation patient and application of the intestinal fungus microorganism model. The invention provides an intestinal tract fungal microorganism model (fungal microorganism distinguishing model) for distinguishing atrial fibrillation patients and non-atrial fibrillation patients, which consists of 15 fungal microorganism genes as shown in SEQ ID NO: 1-15, and the fungal microorganism genes are enriched in human intestinal tracts. The intestinal fungus microbial gene distinguishing model disclosed by the invention realizes good distinguishing ability between atrial fibrillation patients and non-atrial fibrillation patients, and also verifies the feasibility, applicability and universality of the distinguishing model in different regions in China.

The present application relates to a kind of preparation method of fecal bacteria for intestinal flora transplantation.The present application includes the following steps: (1) preparation of intestinal flora reticular carrier; (2) preparation of intestinal flora suspension; (3) preparation of bionic intestine; (4) in vitro continuous culture of intestinal flora; (5) collection after intestinal flora culture.The present application provides a preparation method of fecal bacteria for intestinal flora transplantation, which realizes in vitro culture of intestinal flora by simulating the living environment of intestinal flora in human intestine, ensures the stability of flora quality and yield, eliminates the time limit of intestinal flora transplantation treatment, and greatly improves the timeliness of clinical application.The intestinal flora prepared by the present application has large yield and high activity.Furthermore, the intestinal flora of the present application has obvious improvement in relieving weight loss of inflammatory bowel disease patients, relieving food utilization coefficient decline of inflammatory bowel disease patients, relieving red blood cell quantity decline of inflammatory bowel disease patients, reducing white blood cell quantity of inflammatory bowel disease patients and improving intestinal beneficial bacteria content.

The invention relates to lactobacillus reuteri CBBM002 and application thereof in products for improving immunity, relieving allergy and reducing blood pressure, and belongs to the technical field of microorganism application. The lactobacillus reuteri CBBM002 is preserved in the China General Microbiological Culture Collection Center on March 20, 2025, the preservation number is CGMCCNO.33902, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the lactobacillus reuteri CBBM002 is separated from human intestinal tracts and has the effects of improving immunity, relieving allergy and reducing blood pressure.

This invention discloses a high-purity, multifunctional probiotic powder and its preparation method. Based on the different characteristics of lactic acid bacteria, Bacillus subtilis, and actinomycetes, this invention employs different methods for their respective proliferation. This not only avoids potential mutual interference and contamination during their individual proliferation processes but also achieves high viable cell counts while maintaining high purity, and the high viable cell count is maintained even after mixing. This invention mixes the proliferated bacterial powders in a reasonable ratio, allowing lactic acid bacteria to be the dominant strain while fully utilizing the functional characteristics of each of the three bacteria: lactic acid bacteria are anaerobic, while Bacillus subtilis and actinomycetes are aerobic. The latter can absorb oxygen released by the former, ensuring that in the anaerobic environment of the human intestine, Bacillus subtilis and actinomycetes remain active rather than dormant, generating resistant endospores through synergistic action with lactic acid bacteria.

The present invention provides a method for producing a sarcopenia-inhibiting food product readily available to general consumers, the sarcopenia-inhibiting food product, and a muscle-enhancing food product. In order to solve this problem, this method for producing the sarcopenia-inhibiting food product performs production by fermentation of American ginseng using a microbial group containing at least one of lactic acid bacteria and bifidobacteria. The microbial group preferably contains lactic acid bacteria capable of growing in human intestines. The fermentation is preferably performed for 36-120 hours, inclusive. This sarcopenia-inhibiting food product and this muscle-enhancing food product contain a fermented product of American ginseng using a microbial group containing at least one of lactic acid bacteria and bifidobacteria.

An object of one present invention is to provide a food composition including, as an active ingredient thereof, Lactobacillus mucosae that has a function of improving a gut microbiota. An object of another present invention is to provide an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof. The one present invention provides a composition for improving the gut microbiota, including the bacterial cell or a culture of Lactobacillus mucosae as an active ingredient thereof. The other present invention provides an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof.

The invention relates to the technical field of microorganisms, and particularly discloses lactobacillus paracasei DT66 and application thereof in preparation of products with microplastic adsorption and removal functions. The invention provides a strain of Lactobacillus paracasei DT66, and the preservation number of the strain of Lactobacillus paracasei DT66 is GDMCC No: 63624. The strain of Lactobacillus paracasei DT66 has the preservation number of CGMCC No: 63624. The strain has good acid resistance and cholate resistance, and can be developed into edible probiotics; the microplastics can be adsorbed, discharge of plastics in the body is promoted and accelerated, microplastics residues in the intestinal tract are reduced, accumulated oxidative damage of the microplastics is reduced, and human intestinal tract health is maintained.